- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02696460
Efficacy of 50% Nitrous Oxide/50% Oxygen Gas Premix in Chronic Leg Ulcer Debridement
Efficacy of Inhaled 50% Equimolar Nitrous Oxide/Oxygen Gas Premix (Kalinox®) as Compared to Topically Administered 5% Eutectic Mixture of Lidocaine/Prilocaine (EMLA®) in Chronic Leg Ulcer Debridement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design: Prospective, controlled, single-center, cross-over design study. The study protocol was approved by the local ethical committee.
Study setting/participants: The study is performed in a highly specialized secondary care vein center. Patients with chronic foot and leg ulcer disease that are scheduled for repetitive ulcer debridement are eligible for the study and included into the study provided that written informed consent is obtained and no exclusion criteria are present.
Debridement procedure: For debridement, disposable sterile scalpel blades, ring curettes, and sterilized reusable scissors and forceps are used. The intended sharp mechanical debridement is proceeded as long as it is tolerated by the patient or terminated as planned. It will immediately be discontinued if the patient asks for it due to intolerable pain or discomfort.
Analgesia methods: For analgesia during debridement, either a topically administered eutectic mixture of 5% lidocaine/prilocaine (EMLA®) or an inhaled premix of 50% nitrous oxide/50% oxygen (Kalinox®) are used. The 5% lidocaine/prilocaine cream is administered as a thick layer directly onto the wound with a scoop and the wound is sealed with a polyurethane foil. After 30 minutes of exposure time, the foil is removed and debridement is started immediately. For analgesia with the inhaled 50% nitrous oxide/50% oxygen premix, the patient is asked to hold an inhalation rebreather mask with on-demand-valve tightly placed onto the face after being instructed on how to inhale the gas premix. After 3 minutes of exposure time to the gas premix, debridement is started immediately. Gas inhalation is sustained until final wound dressing is applied. During the entire procedure with each analgesia method, vital signs such as non-invasive blood pressure, heart rate and peripheral oxygen saturation (SpO2) are be recorded.
Allocation of the analgesia regimen: After study enrollment, patients are consecutively numbered starting at one. Even numbered patients have the first debridement done with topical administration of lidocaine/prilocaine cream, followed by inhaled nitrous oxide/oxygen premix for the second debridement, and again followed in an alternating way by both tested analgesia methods up to a maximum of 4 interventions. Uneven numbered patients receive inhaled nitrous oxide/oxygen premix first, followed by topical lidocaine/prilocaine cream. After 4 debridement in total with 2 sets of each analgesia method, the study period for each single patient will be secluded. A maximum of 4 data sets per patient will be brought to data analysis.
Outcome measures: Primary outcome is the change of pain perception from baseline (1 minute before debridement) to time point of maximum debridement/wound profoundness (up to 10 minutes after start of debridement) as measured by the visual analogue scale (VAS). Secondary outcomes are change of pain perception from time point of maximum debridement/wound profoundness to 5 minutes after debridement as measured by the visual analogue scale (VAS), duration of treatment session, duration of debridement, achievement of treatment goal (completion), subjective general perception of analgesia quality during debridement (patient comfort). Baseline characteristics are gender, age, ulcer etiology, time passed between initial ulcer diagnosis and first debridement, wound emergence in terms of suspected trigger for ulcer development, and wound size.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of chronic leg ulcer persisting for more than six weeks despite initial conservative treatment; written informed consent
Exclusion Criteria:
- Other chronic wounds than leg ulcers
- Peripheral polyneuropathy
- Non-specified peripheral sensibility disorders
- Allergies or contraindications against the study agents
- Lack of informed consent
- Pregnancy or breast feeding
- Anticipated need for less than two surgical debridement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: N2O/O2 analgesia
Wound debridement under analgesia with N2O/O2 premix.
|
Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
Other Names:
Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
Other Names:
|
Active Comparator: Lidocaine/Prilocaine analgesia
Wound debridement under analgesia with eutectic mixture of 5% lidocaine/prilocaine.
|
Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
Other Names:
Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Pain Level as Measured by Visual Analogue Scale (VAS)
Time Frame: Change of VAS from Time Point "Baseline 1 Minute before Start of Surgical Debridement" at Time Point "End of Surgical Debridement up to 10 Minutes after Start of Surgical Debridement"
|
Change of measured VAS between Time Point "Baseline", which is 1 Minute Before Start of Surgical Debridement, and Time Point "End of Surgical Debridement", which is at Maximum Wound Profoundness and up to 10 Minutes after Start of Surgical Debridement.
|
Change of VAS from Time Point "Baseline 1 Minute before Start of Surgical Debridement" at Time Point "End of Surgical Debridement up to 10 Minutes after Start of Surgical Debridement"
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Pain Level as Measured by Visual Analogue Scale (VAS)
Time Frame: Change of VAS from Time Point "End of Surgical Debridement" at Time Point "5 Minutes After Surgical Debridement"
|
Change of measured VAS between Time Point "End of Surgical Debridement", which is at Maximum Wound Profoundness during Debridement, and Time Point "5 Minutes after Surgical Debridement".
|
Change of VAS from Time Point "End of Surgical Debridement" at Time Point "5 Minutes After Surgical Debridement"
|
Overall Duration of Treatment Session
Time Frame: From Admission to Discharge up to 60 Minutes
|
Time Patient Spent in Outpatient Clinic for Treatment Session
|
From Admission to Discharge up to 60 Minutes
|
Duration of Wound Debridement
Time Frame: From Start to End of Debridement up to 10 Minutes
|
Total Procedure Time of Debridement
|
From Start to End of Debridement up to 10 Minutes
|
Achievement of Treatment Goal
Time Frame: From Start to End of Debridement up to 10 Minutes
|
Surgeon's Judgement whether Debridement was Completed as Planned or Interrupted Prematurely due to Pain and/or Patient Discomfort.
|
From Start to End of Debridement up to 10 Minutes
|
Overall Analgesia Quality
Time Frame: From Start to End of Debridement up to 10 Minutes
|
Patient's Subjective Perception of Analgesia Quality within the Time Frame of Debridement.
|
From Start to End of Debridement up to 10 Minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Juerg Traber, MD, Venenklinik Bellevue
Publications and helpful links
General Publications
- Bauer C, Lahjibi-Paulet H, Somme D, Onody P, Saint Jean O, Gisselbrecht M. Tolerability of an equimolar mix of nitrous oxide and oxygen during painful procedures in very elderly patients. Drugs Aging. 2007;24(6):501-7. doi: 10.2165/00002512-200724060-00006.
- Onody P, Gil P, Hennequin M. Safety of inhalation of a 50% nitrous oxide/oxygen premix: a prospective survey of 35 828 administrations. Drug Saf. 2006;29(7):633-40. doi: 10.2165/00002018-200629070-00008.
- Zwakhalen SM, Hamers JP, Berger MP. Improving the clinical usefulness of a behavioural pain scale for older people with dementia. J Adv Nurs. 2007 Jun;58(5):493-502. doi: 10.1111/j.1365-2648.2007.04255.x. Epub 2007 Apr 17. Erratum In: J Adv Nurs. 2008 Sep;63(5):537.
- Annequin D, Carbajal R, Chauvin P, Gall O, Tourniaire B, Murat I. Fixed 50% nitrous oxide oxygen mixture for painful procedures: A French survey. Pediatrics. 2000 Apr;105(4):E47. doi: 10.1542/peds.105.4.e47.
- Evans E, Gray M. Do topical analgesics reduce pain associated with wound dressing changes or debridement of chronic wounds? J Wound Ostomy Continence Nurs. 2005 Sep-Oct;32(5):287-90. doi: 10.1097/00152192-200509000-00002. No abstract available.
- Hee HI, Goy RW, Ng AS. Effective reduction of anxiety and pain during venous cannulation in children: a comparison of analgesic efficacy conferred by nitrous oxide, EMLA and combination. Paediatr Anaesth. 2003 Mar;13(3):210-6. doi: 10.1046/j.1460-9592.2003.01051.x.
- Doughty DB. Strategies for minimizing chronic wound pain. Adv Skin Wound Care. 2006 Mar;19(2):82-5. doi: 10.1097/00129334-200603000-00009. No abstract available.
- Rosenthal D, Murphy F, Gottschalk R, Baxter M, Lycka B, Nevin K. Using a topical anaesthetic cream to reduce pain during sharp debridement of chronic leg ulcers. J Wound Care. 2001 Jan;10(1):503-5. doi: 10.12968/jowc.2001.10.1.26042.
- Holm J, Andren B, Grafford K. Pain control in the surgical debridement of leg ulcers by the use of a topical lidocaine--prilocaine cream, EMLA. Acta Derm Venereol. 1990;70(2):132-6.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Ulcer
- Leg Ulcer
- Skin Ulcer
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Anesthetics, Combined
- Lidocaine
- Prilocaine
- Lidocaine, Prilocaine Drug Combination
Other Study ID Numbers
- VB_01_2010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Leg Ulcer
-
University Hospital, GhentJohnson & Johnson; MedtronicCompletedChronic Lower Leg UlcerBelgium
-
Fisher and Paykel HealthcareRecruiting
-
SoftOx Solutions ASCompletedVenous Leg Ulcer | Chronic Leg UlcerDenmark
-
MolecuLight Inc.Scarborough Rouge HospitalUnknownWound | Wound Contamination | Chronic Leg UlcerCanada
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Assistance Publique - Hôpitaux de ParisSociété de Dermatologie FrançaiseCompleted
-
Macrocure Ltd.UnknownChronic Venous Leg UlcersUnited States
-
Kringle Pharma Europe ABKringle Pharma, Inc.UnknownChronic Venous Leg UlcersNorway, Sweden
-
Osiris TherapeuticsTerminated
-
Inotec AMD LimitedWithdrawnSkin Ulcer Venous Stasis Chronic | Mixed Arteriovenous Leg UlcerCzechia
Clinical Trials on N2O/O2 analgesia
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Sheba Medical CenterNot yet recruitingPain Alleviation | Dilatation and Evacuation | Laminaria Placement | Nitrous OxideIsrael
-
University of ChicagoNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Alcohol-Related Disorders | Opioid-Related DisordersUnited States
-
University Hospital, ToulouseRecruitingPneumonia | Pneumonia, Ventilator-Associated | Length of StayFrance
-
Ganin Fertility CenterUnknownEmbryo DevelopmentEgypt
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityCompleted
-
Centre Hospitalier Universitaire Saint PierreCompletedBronchoscopy | O2-supplementationBelgium
-
University of ChicagoNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Opioid-Related DisordersUnited States